Literature DB >> 11110701

Antiadhesive function of 130-kd glycoform of CD43 expressed in CD4 T-lymphocyte clones and transfectant cell lines.

M Fukuoka1, K Fukudome, Y Yamashita, M Tokushima, K Miyake, M Kimoto.   

Abstract

Conflicting findings regarding proadhesion and antiadhesion in cell-to-cell interactions were previously reported for CD43. We examined possible differences in the role of the 130-kd glycoform and the 115-kd glycoform of CD43 in cellular adhesion in vitro. We generated a monoclonal antibody (MFT3) that discriminates between helper and nonhelper murine T-cell clones. Characterization of MFT3 with use of biochemical analysis and complementary DNA (cDNA) transfection experiments showed that it is specific for the 130-kd glycoform of CD43. T-cell clones that expressed the 130-kd CD43 glycoform showed decreased homocytic aggregation and decreased adhesion to spleen cells, B-lymphoma cell lines, and fibroblastic cell lines compared with T-cell clones negative for the 130-kd glycoform. Expression of core 2 beta-1, 6-N-acetylglucosaminyltransferase (C2GnT) cDNA together with CD43 cDNA resulted in expression of both the 130-kd CD43 glycoform and the 115-kd CD43 glycoform in fibroblastic cell lines. Using these cell lines, we showed that the 130-kd glycoform but not the 115-kd glycoform of CD43 has an antiadhesive function in cellular interactions. Our findings suggest that the antiadhesive function of CD43 is primarily carried out by the 130-kd glycoform. (Blood. 2000;96:4267-4275)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110701

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

1.  Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy.

Authors:  Q Fu; S E Cash; J J Andersen; C R Kennedy; A R Madadi; M Raghavendra; L L Dietrich; W A Agger; C S Shelley
Journal:  Br J Cancer       Date:  2013-11-26       Impact factor: 7.640

2.  Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy.

Authors:  Corinne E Decker; Tara Young; Elizabeth Pasnikowski; Joyce Chiu; Hang Song; Yi Wei; Gavin Thurston; Christopher Daly
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.